Moderator:
Rachel Coleman Drury, Pharm.D.
Panelists:
Emily Heil, Pharm.D., BCPS (AQ-ID), AAHIVP
Bryan Love, Pharm.D., BCPS
Reviewed By:
Stuart T. Haines, Pharm.D., BCPS, BCACP
Citation:
Afdhal N, Reddy R, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014; 370: 1483-93.

Direct-acting antiviral agents for the treatment of hepatitis C infection are revolutionizing how we treat patients.  What is the hype all about? Are these medications worth it?  Our panelists critically examine the results of the ION2 Study, providing insights on these questions and more.